TipRanks
Caribou Biosciences (CRBU)
NASDAQ:CRBU
US Market
Want to see CRBU full AI Analyst Report?

Caribou Biosciences (CRBU) Stock Forecast & Price Target

1,004 Followers
See the Price Targets and Ratings of:

CRBU Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
2 Buy
4 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Caribou
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRBU Stock 12 Month Forecast

Average Price Target

$3.75
▲(127.27% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Caribou Biosciences in the last 3 months. The average price target is $3.75 with a high forecast of $8.00 and a low forecast of $1.00. The average price target represents a 127.27% change from the last price of $1.65.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.22,1.7415384615384615,2.263076923076923,2.7846153846153845,3.3061538461538458,3.827692307692307,4.349230769230769,4.8707692307692305,5.392307692307692,5.913846153846153,6.435384615384614,6.9569230769230765,7.478461538461538,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.22,1.4146153846153846,1.6092307692307692,1.8038461538461539,1.9984615384615385,2.193076923076923,2.3876923076923076,2.582307692307692,2.776923076923077,2.9715384615384615,3.166153846153846,3.3607692307692307,3.5553846153846154,{"y":3.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.22,1.2030769230769232,1.1861538461538461,1.1692307692307693,1.1523076923076923,1.1353846153846154,1.1184615384615384,1.1015384615384616,1.0846153846153845,1.0676923076923077,1.0507692307692307,1.0338461538461539,1.0169230769230768,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$8.00Average Price Target$3.75Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CRBU
H.C. Wainwright
H.C. Wainwright
$11→
Hold
―
Downgraded
10/08/26
Caribou Biosciences downgraded to Neutral from Buy at H.C. WainwrightCaribou Biosciences downgraded to Neutral from Buy at H.C. Wainwright
Leerink Partners Analyst forecast on CRBU
Leerink Partners
Leerink Partners
$4→$1
Hold
-39.39%
Downside
Downgraded
10/07/26
Caribou Biosciences downgraded to Market Perform from Outperform at LeerinkCaribou Biosciences downgraded to Market Perform from Outperform at Leerink
Brookline Capital Markets Analyst forecast on CRBU
Brookline Capital Markets
Brookline Capital Markets
―
Hold
―
Downgraded
10/06/26
Caribou Biosciences downgraded to Hold from Buy at BrooklineCaribou Biosciences downgraded to Hold from Buy at Brookline
RBC Capital Analyst forecast on CRBU
RBC Capital
RBC Capital
$10→$1
Hold
-39.39%
Downside
Downgraded
10/06/26
Caribou Biosciences downgraded to Sector Perform from Outperform at RBC CapitalCaribou Biosciences downgraded to Sector Perform from Outperform at RBC Capital
Bank of America Securities Analyst forecast on CRBU
Bank of America Securities
Bank of America Securities
$6→$5
Buy
203.03%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Pharvaris (NASDAQ: PHVS), Caribou Biosciences (NASDAQ: CRBU) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
Citi
$8
Buy
384.85%
Upside
Assigned
08/13/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Caribou Biosciences (NASDAQ: CRBU), Bristol-Myers Squibb (NYSE: BMY) and Schrodinger (NASDAQ: SDGR)
Evercore ISI Analyst forecast on CRBU
Evercore ISI
Evercore ISI
$11→$13
Buy
687.88%
Upside
Reiterated
03/09/26
Caribou Biosciences price target raised to $13 from $11 at Evercore ISICaribou Biosciences price target raised to $13 from $11 at Evercore ISI
Clear Street Analyst forecast on CRBU
Clear Street
Clear Street
$13
Buy
687.88%
Upside
Reiterated
03/06/26
Clear Street Sticks to Their Buy Rating for Caribou Biosciences (CRBU)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CRBU
H.C. Wainwright
H.C. Wainwright
$11→
Hold
―
Downgraded
10/08/26
Caribou Biosciences downgraded to Neutral from Buy at H.C. WainwrightCaribou Biosciences downgraded to Neutral from Buy at H.C. Wainwright
Leerink Partners Analyst forecast on CRBU
Leerink Partners
Leerink Partners
$4→$1
Hold
-39.39%
Downside
Downgraded
10/07/26
Caribou Biosciences downgraded to Market Perform from Outperform at LeerinkCaribou Biosciences downgraded to Market Perform from Outperform at Leerink
Brookline Capital Markets Analyst forecast on CRBU
Brookline Capital Markets
Brookline Capital Markets
―
Hold
―
Downgraded
10/06/26
Caribou Biosciences downgraded to Hold from Buy at BrooklineCaribou Biosciences downgraded to Hold from Buy at Brookline
RBC Capital Analyst forecast on CRBU
RBC Capital
RBC Capital
$10→$1
Hold
-39.39%
Downside
Downgraded
10/06/26
Caribou Biosciences downgraded to Sector Perform from Outperform at RBC CapitalCaribou Biosciences downgraded to Sector Perform from Outperform at RBC Capital
Bank of America Securities Analyst forecast on CRBU
Bank of America Securities
Bank of America Securities
$6→$5
Buy
203.03%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Pharvaris (NASDAQ: PHVS), Caribou Biosciences (NASDAQ: CRBU) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
Citi
$8
Buy
384.85%
Upside
Assigned
08/13/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Caribou Biosciences (NASDAQ: CRBU), Bristol-Myers Squibb (NYSE: BMY) and Schrodinger (NASDAQ: SDGR)
Evercore ISI Analyst forecast on CRBU
Evercore ISI
Evercore ISI
$11→$13
Buy
687.88%
Upside
Reiterated
03/09/26
Caribou Biosciences price target raised to $13 from $11 at Evercore ISICaribou Biosciences price target raised to $13 from $11 at Evercore ISI
Clear Street Analyst forecast on CRBU
Clear Street
Clear Street
$13
Buy
687.88%
Upside
Reiterated
03/06/26
Clear Street Sticks to Their Buy Rating for Caribou Biosciences (CRBU)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
ONCBeOne Medicines
IRLAIRulya Therapeutics
IDYAIDEAYA Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Caribou Biosciences

3 Months
Alec StranahanBank of America Securities
Success Rate
6/12 ratings generated profit
50%
Average Return
+16.59%
Copying Alec Stranahan's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +16.59% per trade.
1 Year
Alec StranahanBank of America Securities
Success Rate
2/12 ratings generated profit
17%
Average Return
-18.48%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -18.48% per trade.
2 Years
Alec StranahanBank of America Securities
Success Rate
0/12 ratings generated profit
0%
Average Return
-58.43%
Copying Alec Stranahan's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -58.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRBU Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
10
9
6
3
3
Buy
0
0
0
0
0
Hold
0
0
0
0
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
9
6
3
7
In the current month, CRBU has received 3 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. CRBU average Analyst price target in the past 3 months is 3.75.
Each month's total comprises the sum of three months' worth of ratings.

CRBU Financial Forecast

CRBU Earnings Forecast

The previous quarter’s earnings for CRBU were -$0.24.
The previous quarter’s earnings for CRBU were -$0.24.

CRBU Sales Forecast

The previous quarter’s earnings for CRBU were $1.50M.
The previous quarter’s earnings for CRBU were $1.50M.

CRBU Stock Forecast FAQ

What is CRBU’s average 12-month price target, according to analysts?
Based on analyst ratings, Caribou Biosciences’s 12-month average price target is 3.75.
    What is CRBU’s upside potential, based on the analysts’ average price target?
    Caribou Biosciences has 127.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CRBU a Buy, Sell or Hold?
          Caribou Biosciences has a consensus rating of Moderate Buy which is based on 2 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Caribou Biosciences’s price target?
            The average price target for Caribou Biosciences is 3.75. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $8.00 ,the lowest forecast is $1.00. The average price target represents 127.27% Increase from the current price of $1.65.
              What do analysts say about Caribou Biosciences?
              Caribou Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of CRBU?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.